Inhibition of protein-protein interactions using biodegradable depsipeptide nanoassemblies.

Area of Science:

• Biotechnology
• Materials Science
• Pharmacology

Background:

• Peptides often exhibit poor pharmacokinetic properties, limiting their therapeutic applications.
• Nanostructures can be engineered to possess favorable pharmacokinetic profiles.
• Peptide inhibitors targeting intracellular protein-protein interactions (PPIs) are a promising therapeutic strategy.

Purpose of the Study:

• To design and develop biodegradable self-assembled depsipeptide nanostructures (SdPNs) that integrate peptide inhibitors for enhanced therapeutic delivery.
• To overcome the limitations of poor peptide pharmacokinetics and complex encapsulation processes.
• To evaluate the in vivo efficacy of SdPNs for tumor targeting and PPI inhibition.

Main Methods:

• Consolidation of nonpolar peptide inhibitors into biodegradable self-assembled depsipeptide nanostructures (SdPNs).
• In vivo evaluation of optimized SdPNs for tumor targeting and PPI inhibition compared to small molecule inhibitors.
• Analysis of PPI inhibition kinetics for both SdPNs and small molecule inhibitors.

Main Results:

• Optimized SdPNs demonstrated superior tumor targeting and PPI inhibition compared to small molecule inhibitors in vivo.
• SdPNs exhibited gradual and controllable PPI inhibition kinetics, unlike the rapid kinetics of small molecules.
• The modular nature of SdPNs allows for the incorporation of various peptide inhibitors without pharmacokinetic concerns.

Conclusions:

• Biodegradable self-assembled depsipeptide nanostructures (SdPNs) offer a viable platform to enhance the therapeutic potential of peptide inhibitors.
• SdPNs effectively address the pharmacokinetic challenges associated with peptide-based drugs.
• This nanostructure platform holds promise for improved targeted cancer therapies by inhibiting intracellular protein-protein interactions.